• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of Pediatric Advisory Committee (PAC) related activities in the month

Dictionary:
The Office of Pediatric Therapeutics plans and coordinates all aspects of FDA’s Pediatric Advisory Committee (PAC) meetings. This effort includes meeting management, recruitment and maintenance of PAC members and Special Government Employees (SGE) experts, conflict of interest (COI) analysis and logistics.


Pediatric Advisory Committee meetings are announced in the Federal Register and are open to the public, unless otherwise stated. The Pediatric Advisory Committee advises and makes recommendations to the Commissioner of Food and Drugs on matters relating to pediatric therapeutics (including drugs and biological products) and medical devices, pediatric research, pediatric ethical issues and any other matter involving pediatrics for which the Food and Drug Administration has regulatory responsibility. The committees are established to provide functions which support the FDA's mission of protecting and promoting the public health and safety of children.


Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in pediatric research, pediatric subspecialties, statistics, and/or biomedical ethics. The core of voting members shall also include one representative from a relevant patient or patient-family organization and may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests and one non-voting member who represents a pediatric health organization.


In advance of each meeting, the Office of Pediatric Therapeutics, in accordance with the Federal Advisory Committee Act, coordinates all aspects of the Pediatric Advisory Committee. This effort includes the recruitment, identification, selection and appointment of well-qualified committee members and consulting experts. In addition, the Office of Pediatric Therapeutics coordinates all logistical matters associated with the meeting (e.g. member availability, travel, lodging, etc).


In order to participate in a meeting, members of the committee and other required experts are screened to identify potential conflicts of interest to all matters to be discussed at the meeting.A Federal employee may not participate personally and substantially in a particular matter in which, to his knowledge, he, his spouse, minor child, general partner, organization in which he is serving as officer, director, trustee, general partner or employee, or any person or organization with whom he is negotiating or has any arrangement concerning prospective employment, has a financial interest.

Information is current as of September 30, 2014.

Fiscal Year - 2015

Skip graphic and jump to text data

TimeTargetNumber of Activities
Oct 2014N/A341
Nov 2014N/A275
Dec 2014N/A190
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 806

Conflict of Interest (COI) matters (includes screening forms for financial interests, discussion, analysis, meetings, waiver determination)

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A51
Nov 2014N/A42
Dec 2014N/A26
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 119

Federal Register (FR) Notices (includes document development, clearance, publication and communications)

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A0
Nov 2014N/A0
Dec 2014N/A0
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 0

Logistical (includes contract development, communications with committee members, orientation, travel, hotel, budget, and records maintenance)

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A126
Nov 2014N/A76
Dec 2014N/A102
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 304

Special Government Employee (SGE) matters (includes evaluation and maintenance of all CVs, academic and scientific qualifications, personnel action files, nomination packets, communications, recruitment, polling, and award materials)

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A94
Nov 2014N/A122
Dec 2014N/A31
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 247

Advisory Committee Member matters (includes evaluation and maintenance of personnel action files in accord with FACA requirements, communications, nomination packages, recruitment, polling, term extensions)

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A70
Nov 2014N/A35
Dec 2014N/A31
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 136

Advisory Committee meetings held (including Pac interaction with other Advisory Committee meetings)

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A0
Nov 2014N/A0
Dec 2014N/A0
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 0

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.